Statistiques de base
| CIK | 1847416 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Orion Biotech Opportunities Corp - Units (1 Ord Share Class A & 1/5 War)
SEC Filings (Chronological Order)
Cette page fournit une liste complète et chronologique des documents déposés auprès de la SEC, à l'exclusion des documents relatifs à la participation que nous fournissons ailleurs.
| February 14, 2024 |
SC 13G/A 1 oriaa121424.htm 683 CAPITAL MANAGEMENT, LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Orion Biotech Opportunities Corp. (Name of Issuer) Class A Ordinary Shares, par value $0.0001 (Title of Class of Securities) G6780C125 (CUSIP Number) December 31, 2023 (Date of Event which Requires F |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-40410 ORION BIOTECH OPPORTUNITIES CORP. (Exact name of registrant as sp |
|
| May 1, 2023 |
UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0080 Washington, D. |
|
| April 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2023 Orion Biotech Opportunities Corp. (Exact name of registrant as specified in its charter) Cayman Islands 001-40410 98-1583924 (State or other jurisdiction of incorporati |
|
| April 24, 2023 |
Exhibit 99.1 Orion Biotech Opportunities Corp. will redeem its Public Shares and will not consummate an initial business combination New York, New York, April 24, 2023 – Orion Biotech Opportunities Corp. (the “Company”) (Nasdaq: ORIA), a special purpose acquisition company, today announced that it will redeem all of its outstanding Class A ordinary shares, par value $0.0001 per share (the “Public |
|
| March 29, 2023 |
Exhibit 4.1 DESCRIPTION OF SECURITIES We are a Cayman Islands exempted company and our affairs are governed by our amended and restated memorandum and articles of association, the Companies Act and the common law of the Cayman Islands. Pursuant to our amended and restated memorandum and articles of association we are authorized to issue 500,000,000 Class A ordinary shares and 50,000,000 Class B or |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ORION BIOTECH OPPORTUNITIES CORP. (Exact name of re |
|
| February 14, 2023 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Orion Biotech Opportunities Corp. (Name of Issuer) Class A ordinary shares, $0.0001 par value per share (Title of Class of Securities) G6780C109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the a |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Orion Biotech Opportunities Corp. (Exact name of r |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Orion Biotech Opportunities Corp. (Exact name of regist |
|
| May 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Orion Biotech Opportunities Corp. (Exact name of regis |
|
| March 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ORION BIOTECH OPPORTUNITIES CORP. (Exact name of re |
|
| March 24, 2022 |
Exhibit 4.1 DESCRIPTION OF SECURITIES We are a Cayman Islands exempted company and our affairs are governed by our amended and restated memorandum and articles of association, the Companies Act and the common law of the Cayman Islands. Pursuant to our amended and restated memorandum and articles of association we are authorized to issue 500,000,000 Class A ordinary shares and 50,000,000 Class B or |
|
| February 14, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2. (Amendment No. )* Orion Biotech Opportunities Corp. (Name of Issuer) Class A ordinary shares, $0.0001 par value per share (Title of Class of Securities) G6780C109 (CUSIP Num |
|
| February 14, 2022 |
ORIAU / Orion Biotech Opportunities Corp. Units / FIR TREE CAPITAL MANAGEMENT LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| December 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2021 ORION BIOTECH OPPORTUNITIES CORP. (Exact name of registrant as specified in its charter) Cayman Islands 001-40410 98-1583924 (State or other jurisdiction of |
|
| December 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2021 ORION BIOTECH OPPORTUNITIES CORP. (Exact name of registrant as specified in its charter) Cayman Islands 001-40410 98-1583924 (State or other jurisdiction of |
|
| December 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Orion Biotech Opportunities Co |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Orion Biotech Opportunities Corp. (Exact name of r |
|
| October 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Orion Biotech Opportunities Corp. (Name of Issuer) Class A ordinary shares, $0.0001 par value per share, included as part of the Units (Title of Class of Securities) G6780C125** (CUSIP Number) May 14, 2021 (Date of Event which Requires Filing of this Stat |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Orion Biotech Opportunities Corp. (Exact name of regist |
|
| July 2, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2021 ORION BIOTECH OPPORTUNITIES CORP. (Exact name of registrant as specified in its charter) Cayman Islands 001-40410 98-1583924 (State or other jurisdiction of incor |
|
| July 2, 2021 |
Exhibit 99.1 Orion Biotech Opportunities Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants Commencing July 2, 2021 July 1, 2021 ? Orion Biotech Opportunities Corp. (Nasdaq: ORIAU) (the ?Company? or ?us?) announced that, commencing July 2, 2021, holders of the units sold in the Company?s initial public offering of 20,000,000 units, completed on May 17, 2021, may elect |
|
| June 29, 2021 |
SC 13G 1 orion13g-062921.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. )* Orion Biotech Opportunities Corp. (Name of Issuer) Class A Ordinary Shares, par value $0.0001 (Title of Class of Securities) G6780C125 |
|
| June 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Orion Biotech Opportunities Corp. (Exact name of registrant as s |
|
| May 21, 2021 |
Financial Statements and Exhibits, Other Events 8-K 1 ea140990-8korionbiotech.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2021 ORION BIOTECH OPPORTUNITIES CORP. (Exact name of registrant as specified in its charter) Cayman Islands 001-40410 |
|
| May 21, 2021 |
Vellar Opportunities Fund Master, Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| May 21, 2021 |
ORION BIOTECH OPPORTUNITIES CORP. Exhibit 99.1 ORION BIOTECH OPPORTUNITIES CORP. Report of Independent Registered Public Accounting Firm F-2 Balance Sheet as of May 17, 2021 F-3 Notes to Financial Statement F-4 F-1 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Shareholders and the Board of Directors of Orion Biotech Opportunities Corp. Opinion on the Financial Statement We have audited the accompanying balance she |
|
| May 18, 2021 |
EX-10.2 5 ea140989ex10-2orionbio.htm PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT, DATED MAY 12, 2021, BETWEEN THE COMPANY AND THE SPONSOR Exhibit 10.2 Execution Version PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT THIS PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT (as it may from time to time be amended and including all exhibits referenced herein, this “Agreement”), dated as of May 12, 2021, i |
|
| May 18, 2021 |
Exhibit 99.2 Orion Biotech Opportunities Corp. Announces Closing of $200 Million Initial Public Offering of Securities NEW YORK, May 17, 2021 ? Orion Biotech Opportunities Corp. (the ?Company?) today announced the closing of its initial public offering (?IPO?) of 20,000,000 units at a price of $10.00 per unit, resulting in Total gross proceeds of $200,000,000. The Company?s units began trading on |
|
| May 18, 2021 |
Exhibit 10.1 Execution Version WARRANT AGREEMENT Orion biotech OPPORTUNITIES Corp. and CONTINENTAL STOCK TRANSFER & TRUST COMPANY Dated May 12, 2021 THIS WARRANT AGREEMENT (this ?Agreement?), dated May 12, 2021, is by and between Orion Biotech Opportunities Corp., a Cayman Islands exempted company (the ?Company?), and Continental Stock Transfer & Trust Company, a New York corporation, as warrant a |
|
| May 18, 2021 |
Orion Biotech Opportunities Corp. Announces Pricing of $200,000,000 Initial Public Offering Exhibit 99.1 Orion Biotech Opportunities Corp. Announces Pricing of $200,000,000 Initial Public Offering NEW YORK, May 12, 2021 ? Orion Biotech Opportunities Corp. (the ?Company?) today announced the pricing of its initial public offering (?IPO?) of 20,000,000 units at a price of $10.00 per unit. The units will be listed on The Nasdaq Capital Market LLC (the ?Nasdaq?) and trade under the symbol ?O |
|
| May 18, 2021 |
Exhibit 10.3 Execution Version INVESTMENT MANAGEMENT TRUST AGREEMENT? This Investment Management Trust Agreement (this ?Agreement?) is made effective as of May 12, 2021 by and between Orion Biotech Opportunities Corp., a Cayman Islands exempted company (the ?Company?), and Continental Stock Transfer & Trust Company, a New York corporation (the ?Trustee?). WHEREAS, the Company?s registration statem |
|
| May 18, 2021 |
Exhibit 10.7 Execution Version FORWARD PURCHASE AGREEMENT This Forward Purchase Agreement (this ?Agreement?) is entered into as of May 12, 2021, by and between Orion Biotech Opportunities Corp., a Cayman Islands exempted company (the ?Company?), and the party listed as the purchaser on the signature page hereof (the ?Purchaser?). WHEREAS, the Company was incorporated for the purpose of effecting a |
|
| May 18, 2021 |
Administrative Services Agreement, dated May 12, 2021, between the Company and the Sponsor.(2) EX-10.6 9 ea140989ex10-6orionbio.htm ADMINISTRATIVE SERVICES AGREEMENT, DATED MAY 12, 2021, BETWEEN THE COMPANY AND THE SPONSOR Exhibit 10.6 Execution Version ORION BIOTECH OPPORTUNITIES CORP. 645 Fifth Avenue, 21st Floor New York, New York 10022 May 12, 2021 Orion Sponsor Holdings, LLC 645 Fifth Avenue, 21st Floor New York, New York 10022 Ladies and Gentlemen: This letter will confirm our agreeme |
|
| May 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2021 ORION BIOTECH OPPORTUNITIES CORP. (Exact name of registrant as specified in its charter) Cayman Islands 001-40410 98- 1583924 (State or other jurisdiction of inco |
|
| May 18, 2021 |
Underwriting Agreement, dated May 12, 2021, between the Company and Cantor Fitzgerald & Co. Exhibit 1.1 UNDERWRITING AGREEMENT between ORION BIOTECH OPPORTUNITIES CORP. and CANTOR FITZGERALD & CO. Dated: May 12, 2021 ORION BIOTECH OPPORTUNITIES CORP. UNDERWRITING AGREEMENT New York, New York May 12, 2021 Cantor Fitzgerald & Co. 499 Park Avenue New York, New York 10022 As Representative of the Underwriters named on Schedule A hereto Ladies and Gentlemen: The undersigned, Orion Biotech Opp |
|
| May 18, 2021 |
EX-10.5 8 ea140989ex10-5orionbio.htm LETTER AGREEMENT, DATED MAY 12, 2021, AMONG THE COMPANY, THE SPONSOR AND THE COMPANY'S EXECUTIVE OFFICERS AND DIRECTORS Exhibit 10.5 Execution Version May 12, 2021 Orion Biotech Opportunities Corp. 645 Fifth Avenue, 21st Floor New York, New York 10022 Re: Initial Public Offering Ladies and Gentlemen: This letter (this “Letter Agreement”) is being delivered to y |
|
| May 18, 2021 |
Exhibit 10.4 Execution Version REGISTRATION AND SHAREHOLDER RIGHTS AGREEMENT THIS REGISTRATION AND SHAREHOLDER RIGHTS AGREEMENT (this ?Agreement?), dated as of May 12, 2021, is made and entered into by and among Orion Biotech Opportunities Corp., a Cayman Islands exempted company (the ?Company?), Orion Sponsor Holdings, LLC, a Cayman Islands limited liability company (the ?Sponsor?), and the under |
|
| May 18, 2021 |
Amended and Restated Memorandum and Articles of Association.(2) Exhibit 3.1 THE COMPANIES ACT (AS REVISED) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION OF Orion Biotech Opportunities Corp. (adopted by special resolution dated 12 May 2021) THE COMPANIES ACT (AS REVISED) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES AMENDED AND RESTATED MEMORANDUM OF ASSOCIATION OF Orion Biotech Opportunities Corp. |
|
| May 14, 2021 |
Filed Pursuant to Rule 424(b)(4) Registration No. 333-253548 424B4 1 f424b4orionbiotech.htm PROSPECTUS Filed Pursuant to Rule 424(b)(4) Registration No. 333-253548 PROSPECTUS $200,000,000 Orion Biotech Opportunities Corp. 20,000,000 Units Orion Biotech Opportunities Corp. is a newly organized blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorgan |
|
| May 12, 2021 |
8-A12B 1 ea140734-8a12borionbio.htm FOR REGISTRATION OF CERTAIN CLASSES UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 ORION BIOTECH OPPORTUNITIES CORP. (Exact Name Of Registrant As Specified In Its Charter) Cayman Islands 98-1583924 (State of |
|
| May 10, 2021 |
CORRESP 1 filename1.htm May 10, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attn: Thomas Jones Re: Orion Biotech Opportunities Corp. Registration Statement on Form S-1 File No. 333-253548 Ladies and Gentlemen, Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), the undersigned hereby joins |
|
| May 10, 2021 |
Orion Biotech Opportunities Corp. 645 Fifth Avenue, 21st Floor New York, New York 10022 May 10, 2021 CORRESP 1 filename1.htm Orion Biotech Opportunities Corp. 645 Fifth Avenue, 21st Floor New York, New York 10022 May 10, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Orion Biotech Opportunities Corp. Registration Statement on Form S-1 File No. 333-253548 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities |
|
| May 4, 2021 |
Via EDGAR and Federal Express May 3, 2021 Attention: Thomas Jones Geoffrey Kruczek Eiko Yaoita Pyles Andrew Blume United States Securities and Exchange Commission Division of Corporation Finance Office of Manufacturing 100 F Street, N. |
|
| May 4, 2021 |
As filed with the U.S. Securities and Exchange Commission on May 3, 2021. Registration No. 333-253548 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Orion Biotech Opportunities Corp. (Exact name of registrant as specified in its charter) Cayman Islands 6770 98-1583924 (State or other jurisd |
|
| April 12, 2021 |
Consent of Director Nominee — Louisa Rodriguez* Exhibit 99.3 CONSENT OF LOUISA RODRIGUEZ Orion Biotech Opportunities Corp. (the ?Company?) intends to file a Registration Statement on Form S-1 (together with any amendments or supplements thereto, the ?Registration Statement?) registering securities for issuance in its initial public offering. As required by Rule 438 under the Securities Act of 1933, as amended, the undersigned hereby consents to |
|
| April 12, 2021 |
S-1/A 1 fs12021a2orionbiotech.htm REGISTRATION STATEMENT As filed with the U.S. Securities and Exchange Commission on April 9, 2021. Registration No. 333-253548 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Orion Biotech Opportunities Corp. (Exact name of registrant as specified in its cha |
|
| April 12, 2021 |
Form of Forward Purchase Agreement between the Registrant and Purchaser* Exhibit 10.9 FORWARD PURCHASE AGREEMENT This Forward Purchase Agreement (this ?Agreement?) is entered into as of April [?], 2021, by and between Orion Biotech Opportunities Corp., a Cayman Islands exempted company (the ?Company?), and the party listed as the purchaser on the signature page hereof (the ?Purchaser?). WHEREAS, the Company was incorporated for the purpose of effecting a merger, share |
|
| April 1, 2021 |
Exhibit 10.8 March [?], 2021 Orion Biotech Opportunities Corp. 645 Fifth Avenue, 21st Floor New York, New York 10022 Re: Initial Public Offering Ladies and Gentlemen: This letter (this ?Letter Agreement?) is being delivered to you in accordance with the Underwriting Agreement (the ?Underwriting Agreement?) entered into by and between Orion Biotech Opportunities Corp., a Cayman Islands exempted com |
|
| April 1, 2021 |
CORRESP 1 filename1.htm Via EDGAR and Federal Express April 1, 2021 Attention: Thomas Jones Geoffrey Kruczek Eiko Yaoita Pyles Andrew Blume United States Securities and Exchange Commission Division of Corporation Finance Office of Manufacturing 100 F Street, N.E. Washington, D.C. 20549-3561 Re: Orion Biotech Opportunities Corp. Registration Statement on Form S-1 Filed February 25, 2021 File No. 33 |
|
| April 1, 2021 |
Exhibit 10.9 FORWARD PURCHASE AGREEMENT This Forward Purchase Agreement (this ?Agreement?) is entered into as of March [?], 2021, by and between Orion Biotech Opportunities Corp., a Cayman Islands exempted company (the ?Company?), and the party listed as the purchaser on the signature page hereof (the ?Purchaser?). WHEREAS, the Company was incorporated for the purpose of effecting a merger, share |
|
| April 1, 2021 |
Exhibit 10.1 INVESTMENT MANAGEMENT TRUST AGREEMENT? This Investment Management Trust Agreement (this ?Agreement?) is made effective as of March [?], 2021 by and between Orion Biotech Opportunities Corp., a Cayman Islands exempted company (the ?Company?), and Continental Stock Transfer & Trust Company, a New York corporation (the ?Trustee?). WHEREAS, the Company?s registration statement on Form S-1 |
|
| April 1, 2021 |
As filed with the U.S. Securities and Exchange Commission on March 31, 2021. Registration No. 333-253548 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Orion Biotech Opportunities Corp. (Exact name of registrant as specified in its charter) Cayman Islands 6770 98-1583924 (State or other jur |
|
| April 1, 2021 |
Memorandum and Articles of Association.* Exhibit 3.1 THE COMPANIES ACT (As Revised) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES MEMORANDUM AND ARTICLES OF ASSOCIATION OF ORION BIOTECH OPPORTUNITIES CORP. THE COMPANIES ACT (As Revised) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES MEMORANDUM OF ASSOCIATION OF ORION BIOTECH OPPORTUNITIES CORP. 1 The name of the Company is Orion Biotech Opportunities Corp.. 2 The Registered Office of |
|
| April 1, 2021 |
Specimen Ordinary Share Certificate.* EX-4.2 6 fs12021a1ex4-2orionbio.htm SPECIMEN ORDINARY SHARE CERTIFICATE Exhibit 4.2 SPECIMEN CLASS A ORDINARY SHARE CERTIFICATE NUMBER DEFINITIONS SHARES CUSIP [ ] Orion Biotech Opportunities Corp. INCORPORATED UNDER THE LAWS OF THE CAYMAN ISLANDS CLASS A ORDINARY SHARES SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP [ ] This Certifies that is the owner of FULLY PAID AND NON-ASSESSABLE CLASS A ORDINARY |
|
| April 1, 2021 |
Specimen Warrant Certificate.* EX-4.3 7 fs12021a1ex4-3orionbio.htm SPECIMEN WARRANT CERTIFICATE Exhibit 4.3 [Form of Warrant Certificate] [FACE] Number Warrants THIS WARRANT SHALL BE VOID IF NOT EXERCISED PRIOR TO THE EXPIRATION OF THE EXERCISE PERIOD PROVIDED FOR IN THE WARRANT AGREEMENT DESCRIBED BELOW ORION BIOTECH OPPORTUNITIES CORP. Incorporated Under the Laws of the Cayman Islands CUSIP [●] Warrant Certificate This Warran |
|
| April 1, 2021 |
Securities Subscription Agreement, dated February 8, 2021, between the Company and the Sponsor.(1) EX-10.7 16 fs12021a1ex10-7orionbio.htm SECURITIES SUBSCRIPTION AGREEMENT, DATED FEBRUARY 8, 2021, BETWEEN THE REGISTRANT AND THE SPONSOR Exhibit 10.7 Orion Biotech Opportunities Corp. 645 Fifth Ave, 21st Floor New York, NY 10022 5910 February 8, 2021 Orion Sponsor Holdings, LLC 645 Fifth Ave, 21st Floor New York, NY 10022 5910 RE: Securities Subscription Agreement Gentlemen: This agreement (this “ |
|
| April 1, 2021 |
EX-10.2 11 fs12021a1ex10-2orionbio.htm FORM OF REGISTRATION AND SHAREHOLDER RIGHTS AGREEMENT AMONG THE REGISTRANT, THE SPONSOR AND THE HOLDERS SIGNATORY THERETO Exhibit 10.2 REGISTRATION AND SHAREHOLDER RIGHTS AGREEMENT THIS REGISTRATION AND SHAREHOLDER RIGHTS AGREEMENT (this “Agreement”), dated as of March [●], 2021, is made and entered into by and among Orion Biotech Opportunities Corp., a Cayma |
|
| April 1, 2021 |
Promissory Note, dated as of February 8, 2021, issued to the Sponsor. EX-10.6 15 fs12021a1ex10-6orionbio.htm PROMISSORY NOTE, DATED AS OF FEBRUARY 8, 2021, ISSUED TO THE SPONSOR Exhibit 10.6 THIS PROMISSORY NOTE (“NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE |
|
| April 1, 2021 |
Form of Warrant Agreement between Continental Stock Transfer & Trust Company and the Registrant.* Exhibit 4.4 WARRANT AGREEMENT Orion biotech OPPORTUNITIES Corp. and CONTINENTAL STOCK TRANSFER & TRUST COMPANY Dated March [?], 2021 THIS WARRANT AGREEMENT (this ?Agreement?), dated March [?], 2021, is by and between Orion Biotech Opportunities Corp., a Cayman Islands exempted company (the ?Company?), and Continental Stock Transfer & Trust Company, a New York corporation, as warrant agent (in such |
|
| April 1, 2021 |
EX-10.4 13 fs12021a1ex10-4orionbio.htm FORM OF INDEMNITY AGREEMENT Exhibit 10.4 INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this “Agreement”) is made as of March [●], 2021, by and between Orion Biotech Opportunities Corp., a Cayman Islands exempted company (the “Company”), and (“Indemnitee”). WHEREAS, highly competent persons have become more reluctant to serve publicly-held corporations as dire |
|
| April 1, 2021 |
Form of Amended and Restated Memorandum and Articles of Association.* Exhibit 3.2 THE COMPANIES ACT (AS REVISED) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION OF Orion Biotech Opportunities Corp. (adopted by special resolution dated [ ] and effective on [ ]) THE COMPANIES ACT (AS REVISED) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES AMENDED AND RESTATED MEMORANDUM OF ASSOCIATION OF Orion Biotech Opport |
|
| April 1, 2021 |
Form of Underwriting Agreement.* Exhibit 1.1 UNDERWRITING AGREEMENT between ORION BIOTECH OPPORTUNITIES CORP. and CANTOR FITZGERALD & CO. Dated: April [ ], 2021 ORION BIOTECH OPPORTUNITIES CORP. UNDERWRITING AGREEMENT New York, New York April [ ], 2021 Cantor Fitzgerald & Co. 499 Park Avenue New York, New York 10022 As Representative of the Underwriters named on Schedule A hereto Ladies and Gentlemen: The undersigned, Orion Biote |
|
| April 1, 2021 |
Form of Private Placement Warrants Purchase Agreement between the Registrant and the Sponsor.* Exhibit 10.3 PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT THIS PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT (as it may from time to time be amended and including all exhibits referenced herein, this ?Agreement?), dated as of March [?], 2021, is entered into by and between Orion Biotech Opportunities Corp., a Cayman Islands exempted company (the ?Company?), and Orion Sponsor Holdings, LLC, a Caym |
|
| April 1, 2021 |
EX-4.1 5 fs12021a1ex4-1orionbio.htm SPECIMEN UNIT CERTIFICATE Exhibit 4.1 SPECIMEN UNIT CERTIFICATE SEE REVERSE FOR CERTAIN DEFINITIONS Orion Biotech Opportunities Corp. NUMBER UNITS U- CUSIP [ ] UNITS CONSISTING OF ONE CLASS A ORDINARY SHARE AND ONE-FIFTH OF ONE REDEEMABLE WARRANT TO PURCHASE ONE CLASS A ORDINARY SHARE THIS CERTIFIES THAT is the owner of Units. Each Unit (“Unit”) consists of one |
|
| April 1, 2021 |
Form of Administrative Services Agreement between the Registrant and the Sponsor.* EX-10.5 14 fs12021a1ex10-5orionbio.htm FORM OF ADMINISTRATIVE SERVICES AGREEMENT BETWEEN THE REGISTRANT AND THE SPONSOR Exhibit 10.5 ORION BIOTECH OPPORTUNITIES CORP. 645 Fifth Avenue, 21st Floor New York, New York 10022 March [●], 2021 Orion Sponsor Holdings, LLC 645 Fifth Avenue, 21st Floor New York, New York 10022 Ladies and Gentlemen: This letter will confirm our agreement that, commencing on |
|
| February 25, 2021 |
Consent of Director Nominee — James Collins* Exhibit 99.2 CONSENT OF JAMES COLLINS Orion Biotech Opportunities Corp. (the ?Company?) intends to file a Registration Statement on Form S-1 (together with any amendments or supplements thereto, the ?Registration Statement?) registering securities for issuance in its initial public offering. As required by Rule 438 under the Securities Act of 1933, as amended, the undersigned hereby consents to be |
|
| February 25, 2021 |
Power of Attorney (included on signature page of this Registration Statement).* As filed with the U.S. Securities and Exchange Commission on February 25, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Orion Biotech Opportunities Corp. (Exact name of registrant as specified in its charter) Cayman Islands 6770 98-1583924 (State or other jurisdiction of incorpora |
|
| February 25, 2021 |
Consent of Director Nominee — Samuel Broder* Exhibit 99.1 CONSENT OF SAMUEL BRODER Orion Biotech Opportunities Corp. (the ?Company?) intends to file a Registration Statement on Form S-1 (together with any amendments or supplements thereto, the ?Registration Statement?) registering securities for issuance in its initial public offering. As required by Rule 438 under the Securities Act of 1933, as amended, the undersigned hereby consents to be |
